A Dose Escalation Study to Assess the Safety and Tolerability of HMPL-453 in Patients With Advanced Solid Malignancies
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02966171|
Recruitment Status : Terminated (The study was terminated on 23AUG2018 for safety reasons.)
First Posted : November 17, 2016
Last Update Posted : November 21, 2018
|Condition or disease||Intervention/treatment||Phase|
|Solid Tumor||Drug: HMPL-453||Phase 1|
Dose-escalation stage (stage 1): Patients participating in the dose-escalation stage will take a single dose of HMPL-453 on Day 1 and will be followed for one week for safety observations. After one week of observation, if no safety issues occur, patients can continue multiple dosing of HMPL-453 QD and start on the DLT assessment cycles. Each cycle consists of 28-days. Patients are required to draw blood samples for PK and safety analysis at specific time points during the treatment.
The 3+3 design will be employed for the dose escalation and MTD determination. To limit the number of patients being exposed to potentially ineffective doses, one patient will be enrolled and dosed in the initial dose cohort. If there are no DLT or < 2 CTCAE grade 2 toxicities occur in the first treatment cycle, then the study will be escalated to the next dose cohort. Otherwise, the trial will revert to a standard 3+3 design.
Dose-Expansion Stage (Stage 2): This stage is to further evaluate the safety, tolerability, PD profile, and preliminary anti-tumor activity of HMPL-453 at the RP2D in approximately 10 patients with advanced solid tumor. Patients with FGFR dysregulated advanced solid tumors, including but not limited to, advanced gastric cancer, advanced urothelial bladder cancer, or advanced cholangiocarcinoma (patients with cancers of the gallbladder or ampulla of Vater are not eligible) are preferred to be enrolled.
Expansion stage will begin after dose-escalation stage is completed and the MTD/RP2D has been determined. Patients will receive HMPL-453 with 28-day treatment cycles until disease progression, death, intolerable toxicity, no longer benefiting from the study treatment per investigator's discretion, or withdrawal of consent, whichever comes first.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||14 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase I, Open-label, Multi-center, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of HMPL-453 in Patients With Advanced Solid Malignancies|
|Actual Study Start Date :||January 2017|
|Actual Primary Completion Date :||August 23, 2018|
|Actual Study Completion Date :||August 23, 2018|
Two strengths of HMPL-453 tablets (25 mg and 100 mg based on the free base) will be used for clinical studies. The drug products are coated tablets, which are packaged in white induction sealed HDPE bottles. HMPL-453 will be administered to patients as oral tablet(s) on a daily basis, untill disease progression, intolerable toxicity, or death. Dose levels are to be potentially tested in this study include 25, 50, 100, 200, 300, 400, and 500 mg/day.
- Incidence of DLTs by the NCI CTCAE v4.03 [ Time Frame: Cycle 1 (DLT assessment window, 28 days) of multiple dosing peroid ]
- Incidence of AEs, clinically significant laboratory abnormalities, and electrocardiographic (ECG) changes and vital signs [ Time Frame: from first dose to 30 days after last dose of study treatment ]
- maximum plasma concentration (Cmax) [ Time Frame: from first dose to day 56 of multiple dosing peroid ]
- time to reach maximum concentration (Tmax) [ Time Frame: from first dose to day 56 of multiple dosing peroid ]
- terminal half-life (t1/2) [ Time Frame: from first dose to day 56 of multiple dosing peroid ]
- area under the concentration-time curve (AUC0-t) [ Time Frame: from first dose to day 56 of multiple dosing peroid ]
- apparent clearance (CL/F) [ Time Frame: from first dose to day 56 of multiple dosing peroid ]
- Serum phosphate level increases [ Time Frame: from first dose to Day 21 of the last treatment cycle ]
- Objective response rate (ORR) [ Time Frame: Every 8 weeks while being treated with HMPL-453 (expected average of 16 weeks) ]
- Duration of response (DoR) [ Time Frame: Every 8 weeks while being treated with HMPL-453 (expected average of 16 weeks) ]
- Disease Control Rate (DCR) [ Time Frame: Every 8 weeks while being treated with HMPL-453 (expected average of 16 weeks) ]
- Change in tumor size [ Time Frame: Every 8 weeks while being treated with HMPL-453 (expected average of 16 weeks) ]Tumor size is defined as the sum of the lengths of the longest diameters of the RECIST 1.1 target lesions (TLs). Percentage change in tumor size will be determined for patients with measurable disease at baseline and is derived at each visit by the percentage change in the sum of the diameters of TLs compared to baseline.
- Progression free survival (PFS) [ Time Frame: Every 8 weeks while being treated with HMPL-453 (expected average of 16 weeks) ]
- FGFR genetic alterations status [ Time Frame: expected average of 16 weeks ]Dose Escalation stage (optional): to retrospectively determine the FGFR genetic alterations in tumor sections for the patients who have either a complete or partial response as per RECIST 1.1.
- FGFR pathway inhibition by pERK [ Time Frame: from first dose to Day 15 of the first treatment cycle ]Dose expansion stage (optional): explores the FGFR pathway inhibition in the fresh tumor samples pre- and after the treatment of HMPL-453.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02966171
|Australia, New South Wales|
|St Vincent's Cancer Services|
|Sydney, New South Wales, Australia, 2010|
|Chris O'Brien Lifehouse|
|Sydney, New South Wales, Australia, 2050|
|Peninsula and Southeast Oncology|
|Frankston, Victoria, Australia, 3199|
|Monash Medical Centre|
|Melbourne, Victoria, Australia, 3168|
|Study Director:||Weiss Yang||Hutchison Medipharma Limited|